CytoMed Therapeutics (GDTC) said Monday it has signed a five-year business and research collaboration deal with SunAct Cancer Institute.
The companies plan to explore the efficacy, potency, safety, and tolerability of CytoMed's proprietary allogeneic gamma delta T cells to treat different cancers in human subjects through clinical research, CytoMed said.
The joint effort will include a phase 2 investigator-initiated trial in India that will be jointly sponsored by the two companies, CytoMed said.
CytoMed shares were up over 22% in recent Monday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。